JP6959487B2 - 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 - Google Patents

筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 Download PDF

Info

Publication number
JP6959487B2
JP6959487B2 JP2017554902A JP2017554902A JP6959487B2 JP 6959487 B2 JP6959487 B2 JP 6959487B2 JP 2017554902 A JP2017554902 A JP 2017554902A JP 2017554902 A JP2017554902 A JP 2017554902A JP 6959487 B2 JP6959487 B2 JP 6959487B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
actriib
hybrid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017554902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512873A5 (cg-RX-API-DMAC7.html
JP2018512873A (ja
Inventor
ハン，エイチキュー
チョウ，シャオラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2018512873A publication Critical patent/JP2018512873A/ja
Publication of JP2018512873A5 publication Critical patent/JP2018512873A5/ja
Priority to JP2021139606A priority Critical patent/JP7320571B2/ja
Application granted granted Critical
Publication of JP6959487B2 publication Critical patent/JP6959487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
JP2017554902A 2015-04-22 2016-04-12 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 Active JP6959487B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021139606A JP7320571B2 (ja) 2015-04-22 2021-08-30 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562150994P 2015-04-22 2015-04-22
US62/150,994 2015-04-22
US201562262356P 2015-12-02 2015-12-02
US62/262,356 2015-12-02
PCT/US2016/027046 WO2016171948A1 (en) 2015-04-22 2016-04-12 Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021139606A Division JP7320571B2 (ja) 2015-04-22 2021-08-30 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質

Publications (3)

Publication Number Publication Date
JP2018512873A JP2018512873A (ja) 2018-05-24
JP2018512873A5 JP2018512873A5 (cg-RX-API-DMAC7.html) 2019-11-14
JP6959487B2 true JP6959487B2 (ja) 2021-11-02

Family

ID=57144520

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017554902A Active JP6959487B2 (ja) 2015-04-22 2016-04-12 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質
JP2021139606A Active JP7320571B2 (ja) 2015-04-22 2021-08-30 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021139606A Active JP7320571B2 (ja) 2015-04-22 2021-08-30 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質

Country Status (24)

Country Link
US (4) US10913782B2 (cg-RX-API-DMAC7.html)
EP (2) EP3878857A1 (cg-RX-API-DMAC7.html)
JP (2) JP6959487B2 (cg-RX-API-DMAC7.html)
KR (1) KR102777477B1 (cg-RX-API-DMAC7.html)
CN (1) CN107683287B (cg-RX-API-DMAC7.html)
AU (2) AU2016251640B2 (cg-RX-API-DMAC7.html)
CA (1) CA2983440C (cg-RX-API-DMAC7.html)
CY (1) CY1124124T1 (cg-RX-API-DMAC7.html)
DK (1) DK3286206T3 (cg-RX-API-DMAC7.html)
ES (1) ES2856001T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210725T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054232T2 (cg-RX-API-DMAC7.html)
IL (1) IL255070B (cg-RX-API-DMAC7.html)
LT (1) LT3286206T (cg-RX-API-DMAC7.html)
MX (1) MX2017013520A (cg-RX-API-DMAC7.html)
PL (1) PL3286206T3 (cg-RX-API-DMAC7.html)
PT (1) PT3286206T (cg-RX-API-DMAC7.html)
RS (1) RS61881B1 (cg-RX-API-DMAC7.html)
RU (1) RU2733492C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201708351XA (cg-RX-API-DMAC7.html)
SI (1) SI3286206T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100294T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016171948A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201707821B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535675A (ja) * 2016-10-20 2019-12-12 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 新規なハイブリッドａｃｔｒｉｉｂリガンドトラップタンパク質を用いた筋消耗及び骨疾患の治療方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
JP6810702B2 (ja) 2015-04-06 2021-01-06 アクセルロン ファーマ インコーポレイテッド シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
JP7055636B2 (ja) 2015-04-06 2022-04-18 アクセルロン ファーマ インコーポレイテッド ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
US10722558B2 (en) 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
KR102761094B1 (ko) 2016-10-05 2025-02-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
JP7219705B2 (ja) 2016-10-05 2023-02-08 アクセルロン ファーマ インコーポレイテッド ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
EP3600415B1 (en) * 2017-03-24 2025-09-17 Novartis AG Antibody against activin receptor type ii receptor for use in treating heart failure
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CN120535607A (zh) * 2018-01-12 2025-08-26 科乐斯疗法公司 激活素受体iib型变体及其使用方法
AU2019266314B2 (en) 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3142149A1 (en) * 2019-05-30 2020-12-03 Acceleron Pharma, Inc. Actrii-binding proteins and uses thereof
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
KR20220148189A (ko) * 2020-02-03 2022-11-04 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
US20230129812A1 (en) * 2020-02-03 2023-04-27 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EP4121078A4 (en) * 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
BR112022020628A2 (pt) * 2020-04-13 2022-11-29 Celgene Corp Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
IL300362A (en) * 2020-08-20 2023-04-01 Regeneron Pharma Methods to prevent and treat poor cardiac function and covid-19 with activin A antagonists
US20240181007A1 (en) * 2021-01-08 2024-06-06 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
CA3243129A1 (en) 2022-01-28 2023-08-03 35Pharma Inc. Type IIB Activin Receptor Variants and Their Uses
EP4653010A1 (en) * 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
DE60027135T2 (de) 1999-01-21 2007-01-11 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
CN1330664C (zh) * 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
AU2012204098B2 (en) 2001-04-24 2014-05-15 The Johns Hopkins University Use of follistatin to increase muscle mass
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
EP1682584B1 (en) * 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
AU2015200950B2 (en) 2004-07-23 2017-04-27 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
EP1778275A2 (en) 2004-08-12 2007-05-02 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
EP2468290B1 (en) 2006-12-18 2015-04-01 Acceleron Pharma, Inc. Activin-ActRII Antagonists for use in treating anemia
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
WO2013106175A1 (en) * 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US7947646B2 (en) * 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
WO2009038745A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
JP5773868B2 (ja) 2008-06-26 2015-09-02 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
US20100015144A1 (en) 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
US8058229B2 (en) 2008-08-14 2011-11-15 Acceleron Pharma Inc. Method of increasing red blood cell levels or treating anemia in a patient
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MY159483A (en) 2008-11-26 2017-01-13 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
HUE035240T2 (hu) 2009-04-27 2018-05-02 Novartis Ag Készítmények és eljárások az izomerõ növelésére
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
CN113171442B (zh) 2009-08-13 2024-11-15 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
MX340451B (es) 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
JP5836961B2 (ja) 2009-11-03 2015-12-24 アクセルロン ファーマ， インコーポレイテッド 脂肪肝疾患を処置するための方法
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20110268736A1 (en) 2010-04-30 2011-11-03 Children's Medical Center Corporation Method for treating congenital myopathy
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
DK3520805T3 (da) 2011-10-17 2021-04-19 Acceleron Pharma Inc Sammensætninger til behandling af myelofibrose
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
US8871209B2 (en) 2011-11-14 2014-10-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
WO2014066486A2 (en) 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
CA2931615A1 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
KR20160127148A (ko) 2014-03-21 2016-11-02 악셀레론 파마 인코포레이티드 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
EP3131931B1 (en) 2014-04-18 2020-10-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
CA2952231A1 (en) 2014-06-13 2015-12-17 Santa Maria Biotherapeutics, Inc. Formulated receptor polypeptides and related methods
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
CN107533040B (zh) 2014-12-03 2022-03-29 细胞基因公司 激活素-actrii拮抗剂及用于治疗贫血症的用途
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
JP7055636B2 (ja) 2015-04-06 2022-04-18 アクセルロン ファーマ インコーポレイテッド ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
KR20180128405A (ko) 2016-02-22 2018-12-03 악셀레론 파마 인코포레이티드 면역 활성 증가에 사용하기 위한 ActRII 길항제
EP3439741A4 (en) 2016-04-06 2020-05-06 Acceleron Pharma Inc. ALK7 ANTAGONISTS AND USES THEREOF
KR102761094B1 (ko) 2016-10-05 2025-02-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535675A (ja) * 2016-10-20 2019-12-12 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 新規なハイブリッドａｃｔｒｉｉｂリガンドトラップタンパク質を用いた筋消耗及び骨疾患の治療方法

Also Published As

Publication number Publication date
SI3286206T1 (sl) 2021-07-30
AU2016251640B2 (en) 2020-07-16
IL255070B (en) 2022-05-01
US20200362009A1 (en) 2020-11-19
RU2733492C2 (ru) 2020-10-02
RS61881B1 (sr) 2021-06-30
US20220332783A1 (en) 2022-10-20
CY1124124T1 (el) 2022-05-27
MX2017013520A (es) 2018-05-22
CN107683287A (zh) 2018-02-09
ES2856001T3 (es) 2021-09-27
AU2020250216B2 (en) 2022-07-14
CN107683287B (zh) 2022-05-06
KR20180006386A (ko) 2018-01-17
PL3286206T3 (pl) 2021-09-13
JP2022000027A (ja) 2022-01-04
AU2016251640A1 (en) 2017-11-23
EP3878857A1 (en) 2021-09-15
PT3286206T (pt) 2021-04-01
HUE054232T2 (hu) 2021-08-30
RU2017138537A3 (cg-RX-API-DMAC7.html) 2019-08-01
HRP20210725T1 (hr) 2021-06-25
US11292826B2 (en) 2022-04-05
BR112017022658A2 (pt) 2018-07-17
IL255070A0 (en) 2017-12-31
US20240262883A1 (en) 2024-08-08
SG10201913747PA (en) 2020-03-30
EP3286206A4 (en) 2018-12-05
WO2016171948A1 (en) 2016-10-27
US20180148491A1 (en) 2018-05-31
US11932677B2 (en) 2024-03-19
EP3286206B1 (en) 2021-02-17
CA2983440C (en) 2024-03-12
SG11201708351XA (en) 2017-11-29
KR102777477B1 (ko) 2025-03-10
HK1251588A1 (zh) 2019-02-01
RU2017138537A (ru) 2019-05-22
LT3286206T (lt) 2021-06-10
US10913782B2 (en) 2021-02-09
JP2018512873A (ja) 2018-05-24
AU2020250216A1 (en) 2020-11-05
SMT202100294T1 (it) 2021-07-12
EP3286206A1 (en) 2018-02-28
CA2983440A1 (en) 2016-10-27
ZA201707821B (en) 2021-03-31
JP7320571B2 (ja) 2023-08-03
DK3286206T3 (da) 2021-05-03
ZA202007118B (en) 2023-03-29

Similar Documents

Publication Publication Date Title
JP7320571B2 (ja) 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質
US12187783B2 (en) Methods for treating muscle wasting and bone disease using novel hybrid ActRIIB ligand trap proteins
US20250041385A1 (en) Modified actrii proteins and methods of use thereof
JP2023546758A (ja) アクチビンおよび腫瘍壊死因子－アルファの二機能性アンタゴニストならびにその使用
RU2834707C9 (ru) Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
RU2834707C1 (ru) Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
CN116635059A (zh) 激活蛋白和肿瘤坏死因子-α的双功能拮抗剂及其用途
CN116744959A (zh) 肿瘤坏死因子-α和转化生长因子-β的双功能拮抗剂及其用途
HK1251588B (en) Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
BR112017022658B1 (pt) Proteína isolada, composição farmacêutica compreendendo a mesma, e uso da composição

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210830

R150 Certificate of patent or registration of utility model

Ref document number: 6959487

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250